



CROSSJECT HAS CLOSED ITS LAST REFINANCING ROUND : \$ 6 millions in order to move forward its 3 Supergeneric products into late clinical phase

CHENOVE - FRANCE, H1-2013

\$ 6 millions private equity financing round : Following the signing of a major \$ 472m worldwide partnering deal last quarter, CROSSJECT has just closed its \$ 6m refinancing round in order to move forward its 3 Supergeneric products into late clinical phase.

As announced few months ago, this refinancing round is now closed giving to CROSSJECT the financial capacity to move its 3 SUPERGENERIC products into clinical bioequivalence studies in order to reach a market approval by 2015.

APLUSFINANCE, SOFIMAC PARTNERS and several wealthy individuals have joined the reinvesting historical shareholders led by GEMMES VENTURES

According to Patrick Alexandre, CROSSJECT CEO and founder, "Self-injection solutions represent a new paradigm for therapeutic drugs by improving therapeutic results of well known molecules and supporting pharmaco-economics efficiency. SUPERGENERICs or New Therapeutic Entities are offering a very attractive risk/reward ratio in a life cycle management strategy. SUPERGENERICs will be a transformational driver for the pre-filled syringe which is already one of the most dynamic market of the pharmaceutical industry. Self administration is the future of generic and biosimilar products where the fixed doses market is estimated around \$ 150 Bn."

In addition, CROSSJECT would like to thank all stakeholders involved in the operation:

- Due diligence: Sigmund Briant, BONNA AUZAS and Julien Passerat, ODERIS
- Corporate lawyer: Emmanuel Moitie, JURISEM
- Shareholders package : Pierre Karpik, GIDE and Denis Marcheteau, LCDMavocats
- Accountant : Philippe Lafitte, ALCYON
- Auditor: Françoise Garnier, PWC
- Fundraising : Tim Muller, SCIENTEX

CROSSJECT is developing in house 3 supergenerics with strong & key partners for the supply chain of the device and its fulfilling & packaging but intends as well to build partnerships on biosimilars and for life cycle management on biologics and generics currently under pre-filled syringe or pen. CROSSJECT is targeting an IPO soon in order to strengthen its manufacturing capacity.



Downloads available: Videos presenting Zeneo under these links:

- <http://www.scientex.eu/resources/D%C3%A9mo+ZENE0.wmv>
- <http://www.scientex.eu/resources/CROSSJECT+FILM-.wmv>
- <http://www.scientex.eu/resources/How+to+Use+ZENE0.wmv>

Size of ZENE0 in Inches: 3 X 2 X 1.1

About ZENEO technology developed by CROSSJECT since 2001:

SELF INJECTION= ZENEO is very easy to use (just place and push) so the patient is autonomous. No need of nursing and hospital admission (AN IMPROVED HEALTH CARE COST)


AUTOMATIC INJECTION= with a 1/10 second injection, ZENEO is avoiding human factor on injection process and provides a safer use in emergency and acute care (MEDICAL BENEFIT)

TRUE NEEDLE FREE= by avoiding needle fear or reducing pain with viscous products, ZENEO ensures a better adoption by patients (COMPLIANCE INCREASED)

PRE-FILLED= ZENEO warranty that there is no risk of contamination or dosing mistakes induced by human manipulations (SAFETY)

SINGLE USE= no risk of mistakes by double injection... (SECURED SYSTEM)

SC, IM & ID= ZENEO is the sole technology targeting these 3 administration routes (FLEXIBLE)



• CROSSJECT Contact:

Companies interested in partnering with CROSSJECT regarding the use of its disposable and true needle-free self auto-injection system ZENEO® in their life cycle management process on biologics, biosimilars or generics; or participating in its coming IPO process, are welcome to contact:

Dr. Tim MULLER, head of corporate finance & corporate development.



About CROSSJECT :

60L avenue du 14 juillet 21300 CHENOVE – France

Dr Tim MULLER, CBO & Executive Board Member

Mobile: +33 (0) 645 523 540 or +33 (0) 602 510 791

t.muller@crossject.com or tm@scientex.eu

<http://www.CROSSJECT.com>

[Click here to contact CROSSJECT](#)



About SCIENTEX:

From science to stock exchange

SCIENTEX is a french advisory, interim & transition management firm, fully dedicated to European life sciences SMEs.

Scientex founder's is acting as an executive sherpa for C-level managers; offering 4 global & integrated operational supports for their corporate affairs. <http://www.scientex.eu>

[Click here to download Scientex's fact sheet](#)



About BIOTECHNEWS: <http://www.biotechnews.fr/>

BiotechNews is an independent, private, worldwide, life sciences letter with an unique concept:

one letter = one player or one deal

BIOTECHNEWS is now delivered to +250 000 key life sciences professionals including 50% of board members, VP-level & C-level managers. Thanks to an IP partnership, all SCIENTEX's clients (<http://www.scientex.eu>) have a free access to worldwide corporate communication campaigns pushed by BIOTECHNEWS.

Your contact covering Europe : br@biotechnews.fr